Journal of Gynecologic Oncology最新文献

{"title":"Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology.","authors":"Tadahiro Shoji, Tsukasa Baba, Yoichi Kobayashi, Hideki Tokunaga, Satoru Nagase, Kaoru Abiko, Muneaki Shimada, Masashi Takano, Wataru Yamagami, Hiroshi Tanabe, Akitoshi Nakashima, Hiroaki Kajiyama, Mikiko Asai-Sato, Munetaka Takekuma, Kazuhiro Takehara, Tsutomu Tabata, Shin-Ei Noda, Kenichi Harano, Yasuyuki Hirashima, Mayu Yunokawa, Tohru Morisada, Aikou Okamoto","doi":"10.3802/jgo.2026.37.e150","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e150","url":null,"abstract":"<p><p>To present the 2025 revision of the Japan Society of Gynecologic Oncology Clinical Practice Guidelines for the treatment of ovarian, fallopian tube, and primary peritoneal cancers, which incorporates recent advances in surgical strategies, molecular diagnostics, and maintenance therapies within the context of the Japanese healthcare system. Clinical questions (CQs) were formulated using the PICO framework. Systematic literature searches were conducted in PubMed, the Japan Medical Abstract Society, and the Cochrane Library (January 2019-December 2023), along with additional manual searches for emerging evidence. Three new systematic reviews addressing minimally invasive surgery, secondary cytoreductive surgery, and lymphadenectomy for malignant germ cell tumors were performed. Evidence levels and recommendation strengths were determined according to the Minds 2020 methodology adapted to the Japanese clinical and insurance environment. Recommendations were formulated using a modified GRADE approach. Final recommendations were established through multidisciplinary consensus voting, with a predefined agreement threshold of 75%. The sixth edition comprises 6 chapters and 49 CQs. Major updates include expanded guidance on homologous recombination deficiency testing and genomic profiling, refined indications for maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors and bevacizumab, clarified recommendations for secondary cytoreductive surgery, updated management of PARP inhibitor-exposed recurrence, and strengthened sections on onco-fertility and palliative care. Transparency was enhanced by disclosing key discussion points and consensus rates for each recommendation. These guidelines define evidence-based standards tailored to Japanese clinical practice while maintaining international relevance. They aim to reduce inter-institutional disparities, optimize patient outcomes, and provide a transparent framework for future therapeutic integration.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of lymphadenectomy in surgical management of malignant ovarian germ cell tumors: a multi-center retrospective cohort study with inverse propensity of treatment weighting.","authors":"Xinyang Jin, Jiaxin Yang, Kezhen Zhang, Jing Zheng, Tianyu Zhang, Xinyue Zhang, Xuan Zong, Hui Zhang, Hua Li, Peng Peng, Dongyan Cao, Yang Xiang, Jie Yang","doi":"10.3802/jgo.2027.38.e26","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e26","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between lymphadenectomy (LND) and survival outcomes in malignant ovarian germ cell tumors.</p><p><strong>Methods: </strong>In this multi-center, retrospective cohort study, patients surgically treated for malignant ovarian germ cell tumors at three tertiary hospitals in China between 2016 and 2023 were included. Progression-free survival (PFS), surgical performance and perioperative complications were analyzed. An inverse propensity of treatment weighting model was performed to minimize selection bias.</p><p><strong>Results: </strong>A total of 213 patients were eligible for analysis, of whom 57 (26.8%) underwent LND and 156 (73.2%) did not. The overall rate of lymph-node metastasis was 17.5% (immature teratoma 0%, yolk sac tumor 9.5%, dysgerminoma 27.8%). LND was associated with increased operative time (p<0.001), hospital stay (p=0.019) and estimated blood loss (p=0.007). No significant difference was identified in the 5-year PFS between the 2 groups before and after inverse propensity of treatment weighting adjustment. Multivariate analysis showed the delayed post-operative chemotherapy and unfavorable pathological types (yolk sac tumor and mixed malignant germ cell tumors) were independent predictors of survival (hazard ratio [HR]=2.86, 95% confidence interval [CI]=1.27-6.44, p=0.011; HR=2.88, 95% CI=1.03-8.08, p=0.044; and HR=3.90, 95% CI=1.37-11.08, p=0.011, respectively).</p><p><strong>Conclusion: </strong>Our study indicated that LND was not associated with a survival benefit but increased surgical morbidity in patients with malignant ovarian germ cell tumors, underscoring the critical importance of timely chemotherapy. However, it may still be considered in select cases, such as for imaging-suspected dysgerminoma.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment.","authors":"Shiho Kuji, Mohd Faizal Ahmad, Syamel Muhammad, Sarita Kumari, Romelyn Imperio-Onglao, Shohei Iyoshi, Masato Yoshihara, Siew Fei Ngu, Allen Gideon Tan, Sanghoon Lee, Pinyada Panyavaranant, Jennifer Ko, Very Great Eka Putra, Min-Hyun Baek, Rudrika Chandra, Yu Xue, Doris R Benavides, Tingyan Shi, Navamol Lekskul, Angela Cho, Biswajit Dash, Ling Lim, Christine Shan-Chi Chiu, Reeta Mahey, Se Ik Kim, Virgilio M Novero, Geon Woo Lee, Emiri Miyamoto, Motohiro Chosokabe, Motoki Takenaka, Kensuke Sakai, Kosuke Shigematsu, Jae-Weon Kim, Hiroaki Kajiyama, Nao Suzuki","doi":"10.3802/jgo.2027.38.e21","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e21","url":null,"abstract":"<p><strong>Objective: </strong>To examine current practices of fertility preservation (FP) and infertility treatment after fertility-sparing surgery for borderline ovarian tumors (BOTs) across Asian regions.</p><p><strong>Methods: </strong>A cross-national survey was conducted among gynecologic oncology experts in 10 Asian regions (Chinese Mainland, Hong Kong, India, Indonesia, Japan, Malaysia, South Korea, Taiwan, Thailand, and the Philippines) using a 7 survey questions assessing ovarian function monitoring, FP timing and methods, and management after childbirth or recurrence.</p><p><strong>Results: </strong>Ovarian function was routinely monitored in 7 of the 10 regions (70%), although the methods and duration of follow-up varied. Oocyte pickup was performed intraoperatively in 5 of the 10 regions (50%) and postoperatively in 7 of the 10 regions (70%). Three of the 10 regions (30%) routinely performed completion surgery after childbirth, which appeared to be less common in high-income regions. FP in recurrent BOT was considered feasible in 8 regions (80%).</p><p><strong>Conclusion: </strong>Inter regions differences were observed in the adoption of advanced assisted reproductive technologies for BOT and in the prioritization of FP. Because the oncologic safety of these approaches remains supported by limited evidence, further studies are required before their widespread implementation in clinical practice. In addition, consensus based on robust evidence, including oncologic outcomes, is needed regarding the management of recurrence and post-childbirth treatment strategies.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor.","authors":"Shiho Kuji, Syamel Muhammad, Sarita Kumari, Romelyn Imperio-Onglao, Mohd Faizal Ahmad, Shohei Iyoshi, Masato Yoshihara, Siew Fei Ngu, Allen Gideon Tan, Sanghoon Lee, Pinyada Panyavaranant, Jennifer Ko, Very Great Eka Putra, Min-Hyun Baek, Rudrika Chandra, Yu Xue, Doris R Benavides, Tingyan Shi, Navamol Lekskul, Angela Cho, Biswajit Dash, Ling Lim, Christine Shan-Chi Chiu, Reeta Mahey, Se Ik Kim, Virgilio M Novero, Geon Woo Lee, Emiri Miyamoto, Motohiro Chosokabe, Motoki Takenaka, Kensuke Sakai, Kosuke Shigematsu, Jae-Weon Kim, Hiroaki Kajiyama, Nao Suzuki","doi":"10.3802/jgo.2027.38.e24","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e24","url":null,"abstract":"<p><strong>Objective: </strong>Epithelial borderline ovarian tumors (BOTs) commonly affect women of reproductive age, making fertility preservation (FP) an important clinical consideration. This study aimed to evaluate the current status of FP practices for BOT across Asian regions and to identify variations and areas requiring standardization.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted by the Asian Society of Gynecologic Oncology special task force. Ten regions (Japan, South Korea, Chinese Mainland, Taiwan, Hong Kong, Thailand, Indonesia, India, Malaysia, and the Philippines) participated. A 10-item questionnaire addressed indications, surgical approaches, and management strategies for FP in BOT (part I).</p><p><strong>Results: </strong>Seven of the 10 regions (70%) reported an upper age limit for fertility-sparing surgery (FSS), ranging from 35 years to menopause. Indications based on histologic subtype varied across regions. FSS for stage II or higher disease was considered in 7 regions (70%). Laparoscopic surgery was performed in 3 regions (30%), all in East Asia. Lymphadenectomy was performed in 3 regions (30%). Strategies for additional surgery following incomplete initial procedures varied, reflecting differences in prioritization between ovarian preservation and oncologic radicality.</p><p><strong>Conclusion: </strong>Substantial regional variation exists in FP practices for BOT across Asia. Although a general trend toward fertility-sparing strategies is evident, standardization based on high-quality evidence is needed. Future research should focus on optimizing oncologic safety while preserving fertility and supporting shared decision-making in this patient population.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-marketing safety assessment of mirvetuximab soravtansine: a disproportionality analysis based on the FDA Adverse Event Reporting System.","authors":"Haowen Tan, Xuan Ou, Luping Luo, Ying Chen","doi":"10.3802/jgo.2027.38.e27","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e27","url":null,"abstract":"<p><strong>Objective: </strong>Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate that targets the folate receptor-alpha and is used for the treatment of platinum-resistant ovarian cancer, though post-marketing safety data remain limited. This study aimed to perform a post-marketing safety assessment of MIRV based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.</p><p><strong>Methods: </strong>Adverse event (AE) reports of MIRV as the primary suspected drug were collected from the FAERS database (Q4 2022 to Q4 2025). Four main methods of disproportionality analysis, including reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma poisson shrinker, were employed for signal detection. Additionally, clinical priority and time-to-onset characteristics were assessed.</p><p><strong>Results: </strong>Two thousand five hundred eighty-two AEs associated with MIRV were identified in 1,252 unique patients. The system organ classes of eye and gastrointestinal disorders were the most frequently affected by MIRV. Thirty-nine preferred terms (PTs) were detected as positive safety signals. The most frequently reported AEs were vision blurred, neuropathy peripheral, cataract, diarrhea, abdominal pain and pneumonitis. Several unexpected safety signals, including blindness, colitis, pulmonary fibrosis, glaucoma, intestinal perforation, and ulcerative keratitis, were also identified. None of the positive PTs were classified as strong clinical priority. Furthermore, exploratory findings suggest the peak onset period for MIRV-associated AEs appears to be the first month of treatment.</p><p><strong>Conclusion: </strong>This study confirms the known safety profile of MIRV and identifies several unexpected safety signals. However, as these unexpected safety signals are only hypothesis-generating, prospective studies are still required to confirm causality.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endometrial cancer in G20 countries, 1990-2050: trends, projections, and machine learning-based risk drivers.","authors":"Biqing Chen, Haizhu Sun, Xiaohong Qiu","doi":"10.3802/jgo.2027.38.e25","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e25","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate long-term trends and future trajectories of endometrial cancer burden and population-level factors associated with its incidence across G20 countries.</p><p><strong>Methods: </strong>Using Global Burden of Disease 2023 data, we assessed incidence, prevalence, mortality, and disability-adjusted life years (DALYs) among women in G20 countries from 1990 to 2023. Trends were analyzed by age and country using estimated annual percentage change, Joinpoint regression, cluster analysis, and decomposition. Future burden was projected using autoregressive integrated moving average, exponential smoothing, and Bayesian age-period-cohort models. Summary exposure values for 85 risk factors were incorporated into machine-learning models interpreted using SHapley Additive exPlanations (SHAP).</p><p><strong>Results: </strong>Substantial cross-national heterogeneity was observed in 2023. Although absolute case numbers increased in most countries, age-standardized mortality and DALYs generally stabilized or declined. Population ageing and growth primarily drove rising case numbers, whereas epidemiological improvements offset mortality. Projections indicated continued growth in absolute burden. Machine-learning analyses identified nonlinear associations of incidence with age structure, sociodemographic development, and lifestyle-related factors.</p><p><strong>Conclusion: </strong>Endometrial cancer burden in G20 countries is shifting from a mortality-dominated pattern toward increasing chronic health loss, largely because of population ageing and growth. Prevention and control strategies should extend beyond mortality reduction to emphasize risk stratification, early detection, survivorship care, and long-term management. Machine-learning and SHAP findings provide exploratory evidence of population-level exposure profiles associated with incidence and should be considered hypothesis-generating rather than causal.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant sandwich therapy is associated with improved survival in stage III-IVA endometrial cancer: a network meta-analysis.","authors":"Xinyi Chen, Yi Ding, Yuanyuan Liao, Xiaolin Luo, Ting Deng, Dong Yang, Jihong Liu, He Huang","doi":"10.3802/jgo.2026.37.e100","DOIUrl":"10.3802/jgo.2026.37.e100","url":null,"abstract":"<p><strong>Objective: </strong>Patients with advanced endometrial cancer (International Federation of Gynecology and Obstetrics stages III-IVA) face a high risk of recurrence even after surgery. Although adjuvant chemoradiotherapy (CRT) is standard care, the optimal sequencing strategy remains controversial. This research aimed to evaluate the impact of 4 CRT sequencing strategies on survival in patients with stages III-IVA endometrial cancer.</p><p><strong>Methods: </strong>We conducted a network meta-analysis of 9 studies, encompassing 8,401 patients, to compare 4 CRT regimens: concurrent CRT (CCRT), chemotherapy followed by radiotherapy (CR), radiotherapy followed by chemotherapy (RC), and sandwich therapy involving chemotherapy-radiotherapy-chemotherapy (CRC). The primary outcomes were overall survival (OS) and progression-free survival (PFS), which were analyzed using risk ratios (RRs) with 95% confidence intervals (CIs). Treatment rankings were determined based on surface under the cumulative ranking (SUCRA) probabilities.</p><p><strong>Results: </strong>CRC demonstrated superior survival outcomes compared to other regimens, with significantly higher mortality risks observed in comparator groups: for OS, CCRT showed a 99% increased risk (RR=1.99; 95% CI=1.28-3.09), CR 48% (RR=1.48; 95% CI=1.11-1.97), and RC 57% (RR=1.57; 95% CI=1.09-2.26); for PFS, CR exhibited 40% higher recurrence risk (RR=1.40; 95% CI=1.16-1.68) and RC 35% (RR=1.35; 95% CI=1.03-1.77). SUCRA values ranked CRC highest for both OS (92.98%) and PFS (96.32%), with no significant differences in grade ≥3 toxicity across regimens.</p><p><strong>Conclusion: </strong>For patients with stages III-IVA endometrial cancer, CRC is associated with survival benefits without an increase in toxicity. Pending prospective validation, these findings support CRC as the preferred adjuvant regimen.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e100"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of immunohistochemically defined molecular subtypes with substantial lymphovascular space invasion in early-stage endometrial cancer: a single-center cohort of 575 patients.","authors":"Hande Nur Öncü, Şahin Kaan Baydemir, Neslihan Öztürk, Gökçen Ege, Oğuz Kaan Köksal, Firdevs Şahin Duran, Candost Hanedan, Vakkas Korkmaz","doi":"10.3802/jgo.2026.37.e156","DOIUrl":"10.3802/jgo.2026.37.e156","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between immunohistochemically (IHC) defined molecular subtypes and substantial lymphovascular space invasion (LVSI) in early-stage endometrial cancer (EC) according to the International Federation of Gynecology and Obstetrics (FIGO) 2023 classification.</p><p><strong>Methods: </strong>This study included 575 patients who underwent primary surgery for FIGO stage I-II EC between January 2023 and April 2025. LVSI was assessed using World Health Organization criteria and classified as no/focal (Group 1, n=520) or substantial (Group 2, n=55). Molecular subtypes were determined using a surrogate IHC-based approach (no specific molecular profile, mismatch repair-deficient [MMRd], p53-abnormal [p53abn]); POLE mutation analysis was performed in a subset of patients. Clinicopathological variables were compared between groups, and independent predictors of substantial LVSI were identified using multivariable logistic regression.</p><p><strong>Results: </strong>Substantial LVSI was observed in 9.6% of patients (n=55). MMRd (18.5% vs. 34.5%) and p53abn (11% vs. 20%) subtypes were more frequent in the substantial LVSI group (p=0.001). Deep myometrial invasion (≥50%) (21.9% vs. 70.9%, p<0.001), cervical stromal invasion (4.8% vs. 16.4%, p=0.003), and adjuvant therapy (34.6% vs. 92.7%, p<0.001) were also associated with substantial LVSI. Multivariable analysis identified MMRd subtype (adjusted odds ratio [aOR]=2.916; 95% confidence interval [CI]=1.466-5.801; p=0.002) and ≥50% myometrial invasion (aOR=7.935; 95% CI=4.173-15.091; p<0.001) as independent predictors.</p><p><strong>Conclusion: </strong>In early-stage EC, substantial LVSI is associated with the MMRd molecular subtype and deep myometrial invasion. Understanding the molecular tumor biology underlying LVSI may facilitate more individualized risk stratification and treatment strategies.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e156"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Therapeutic efficacy of laser vaporization and conization for high-grade cervical intraepithelial neoplasia.","authors":"Miseon Nakazawa, Mizue Teramoto, Tsuyoshi Saito","doi":"10.3802/jgo.2026.37.e139","DOIUrl":"10.3802/jgo.2026.37.e139","url":null,"abstract":"<p><p>This corrects the article on p. e34 in vol. 37, PMID: 41312632.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"37 5","pages":"e139"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of psoas muscle index at diagnosis in cervical cancer progression.","authors":"Seon-Mi Lee, Hyunkyoung Seo, Seongmin Kim, Hyun-Woong Cho, Kyung-Jin Min, Sanghoon Lee, Jin-Hwa Hong, Jae-Yun Song, Jae-Kwan Lee, Nak-Woo Lee","doi":"10.3802/jgo.2026.37.e95","DOIUrl":"10.3802/jgo.2026.37.e95","url":null,"abstract":"<p><strong>Objective: </strong>To assess whether the psoas muscle index (PMI) measured using computed tomography (CT) at diagnosis can predict cancer progression and overall survival (OS) in patients with cervical cancer.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients diagnosed with cervical cancer at Korea University Anam Hospital from January 2019 to December 2023. Patients with incomplete data or those who were lost to follow-up were excluded. PMI was measured on axial CT images at the third lumbar vertebral (L3) level at diagnosis, defined as the sum of bilateral psoas diameters normalized to height squared (m²), and a cutoff value of 35 mm/m² was used to classify patients into low and high PMI groups. Survival outcomes were assessed using Kaplan-Meier analysis and the log-rank test. Cox proportional hazards models were used to identify prognostic factors.</p><p><strong>Results: </strong>Of the 178 patients, 92 were in the low PMI group and 86 in the high PMI group. Higher PMI was associated with significantly prolonged disease-free survival (DFS) (p<0.001), but not with OS (p=0.395). In multivariate Cox regression analysis, higher PMI independently predicted a lower likelihood of disease progression (adjusted hazard ratio, 0.30; p<0.001). However, PMI was not associated with OS.</p><p><strong>Conclusion: </strong>This study demonstrates that PMI measured at diagnosis may serve as a useful independent prognostic factor for cancer progression in patients with cervical cancer, particularly for predicting DFS.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e95"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}